Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
12 Primary Progressive Multiple Sclerosis Trials Near You
Power is an online platform that helps thousands of Primary Progressive Multiple Sclerosis patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerIDP-023 + Ocrelizumab for Multiple Sclerosis
Kansas City, Kansas
This is an open label, Phase 1b, multiple ascending dose, and dose-expansion study of IDP-023 administered in combination with interleukin-2 (IL-2) and ocrelizumab to evaluate the safety, tolerability, and biologic activity on autoreactive immune cells in patients with refractory progressive multiple sclerosis.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Relapsing MS, CNS Tumor, HIV, Others
Must Be Taking:Ocrelizumab
34 Participants Needed
Azer-cel for Autoimmune Disease
Omaha, Nebraska
The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-cel).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 60
Sex:All
Key Eligibility Criteria
Disqualifiers:Cancer, Hepatitis B, HIV, Transplant, Others
32 Participants Needed
High-Dose Ocrelizumab for Multiple Sclerosis
Sherman, Texas
This trial is testing if a higher dose of ocrelizumab given through an IV drip is more effective and safe for patients with Primary Progressive Multiple Sclerosis (PPMS). The drug works by reducing harmful immune cells to potentially slow down the disease. Ocrelizumab is the first drug approved for treating both relapsing and primary progressive forms of multiple sclerosis.
No Placebo Group
Prior Safety Data
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18 - 55
Sex:All
Key Eligibility Criteria
Disqualifiers:Cancer, Immunocompromised, Infections, Others
Must Not Be Taking:Immunosuppressants, Corticosteroids, CD20s, Others
769 Participants Needed
Gold Nanocrystals for Multiple Sclerosis
Dallas, Texas
REPAIR-MS is a single-center open label, sequential group, investigator and patient blinded study to assess the CNS metabolic effects, safety, pharmacokinetics, and pharmacodynamics of CNM-Au8 in patients who have been diagnosed with Multiple Sclerosis (MS) within fifteen (15) years of Screening. The primary endpoint for this study changes from baseline to week 12 in CNS metabolic changes, based on 31P-MRSimaging.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 55
Sex:All
Key Eligibility Criteria
Disqualifiers:HIV, Hepatitis B/C, Pregnancy, Others
Must Be Taking:Natalizumab, B-cell Depleting, S1P Modulator
30 Participants Needed
Exercise for Multiple Sclerosis
Regina, Saskatchewan
A growing body of work suggests that regular exercise can support symptom management and improve physical function for people living with multiple sclerosis (MS). Although exercise is known to be beneficial for managing many symptoms related to MS, its effects on the central nervous system, and whether these effects change with different types of exercise, are not well understood. Here, the investigators have designed a clinical trial that compares the effects of distinct exercise protocols on aspects of physical function, physical fitness, and central nervous system function. This research will be the first to compare the effects of different types of exercise on central nervous system changes in people with MS.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:High Physical Activity, Seizure History, Other Neurological Conditions, Relapse, Psychiatric Diagnosis, Others
69 Participants Needed
Retinal Imaging for Neurodegenerative Disease
Durham, North Carolina
This trial uses special cameras to take detailed pictures of the back of the eye in people with cognitive impairments or neurodegenerative diseases. Researchers analyze these images to find early signs of these diseases by examining tiny blood vessels in the eye.
No Placebo Group
Trial Details
Trial Status:Recruiting
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Inability To Cooperate, Intraocular Surgery, Others
2000 Participants Needed
Memory Enhancement Training for Multiple Sclerosis
Marlton, New Jersey
This trial is testing a memory improvement method to help people with Multiple Sclerosis (MS) enhance their memory and daily functioning. The technique involves brain training exercises or activities. The modified Story Memory Technique (mSMT) has been shown to improve new learning and memory in individuals with multiple sclerosis (MS).
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18 - 59
Sex:All
Key Eligibility Criteria
Disqualifiers:Stroke, Neurological Injury, Psychiatric Illness, Others
Must Not Be Taking:Exclusionary Medication
120 Participants Needed
Stem Cell Therapy for Neurological Disorders
Coral Springs, Florida
This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http://mdstemcells.com/nest/
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Medically Unstable, Others
500 Participants Needed
CAR T-Cell Therapy for Multiple Sclerosis
Palo Alto, California
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Primary and Secondary Progressive Multiple Sclerosis
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 60
Sex:All
Key Eligibility Criteria
Disqualifiers:HIV, Hepatitis B/C, Stroke, Others
Must Be Taking:Anti-CD20 MAb
120 Participants Needed
CAR T-cell Therapy for Multiple Sclerosis
Palo Alto, California
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:HIV, Hepatitis B, Hepatitis C, Others
Must Not Be Taking:Anticoagulants, Antiplatelets, Anti-CD20
12 Participants Needed
N-acetyl Cysteine for Multiple Sclerosis
San Francisco, California
This trial tests if N-acetyl cysteine (NAC) can help people with progressive multiple sclerosis by protecting brain cells and reducing inflammation. Participants will be divided into two groups, with one group taking NAC. N-acetyl cysteine (NAC) has been studied for its potential benefits in various conditions, including multiple sclerosis, cannabis use disorder, and chronic obstructive pulmonary disease.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:40 - 70
Sex:All
Key Eligibility Criteria
Disqualifiers:MS Relapses, Pregnancy, Bleeding Disorders, Others
Must Be Taking:Disease-modifying Treatments, Dalfampridine
98 Participants Needed
Clemastine Fumarate for Multiple Sclerosis
San Francisco, California
This trial tests Clemastine Fumarate to see if it can repair myelin in patients with relapsing-remitting multiple sclerosis who have chronic brain lesions. The medication helps immature brain cells develop into myelin-producing cells, potentially fixing the damage caused by MS.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 55
Sex:All
Key Eligibility Criteria
Disqualifiers:Brain Atrophy, Cardiac Block, Cancer, Others
Must Not Be Taking:Corticosteroids, Alemtuzumab, Mitoxantrone, Others
74 Participants Needed
Learn More About Power
We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.
Bask GillCEO at Power
Frequently Asked Questions
How much do Primary Progressive Multiple Sclerosis clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.How do Primary Progressive Multiple Sclerosis clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Primary Progressive Multiple Sclerosis trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Primary Progressive Multiple Sclerosis is 12 months.How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.Do I need to be insured to participate in a Primary Progressive Multiple Sclerosis medical study ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.What are the newest Primary Progressive Multiple Sclerosis clinical trials ?
Most recently, we added IDP-023 + Ocrelizumab for Multiple Sclerosis, Azer-cel for Autoimmune Disease and CAR T-Cell Therapy for Multiple Sclerosis to the Power online platform.Popular Searches
By Condition
By Location
Other People Viewed
By Subject
By Trial
Related Searches
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.